| Document |
Document Title |
|
WO/2022/120354A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2022/112072A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.
|
|
WO/2022/093850A1 |
Provided is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, that is a modulator of 5-HT2A and can be used in treating diseases and disorders associated with 5-HT2A serotonin receptor expression and/or activity. T...
|
|
WO/2022/088306A1 |
A method for preparing an intermediate 4,4-dimethylisoxazol-3-one. In the method 3-chloro-2-methylpropene, carbon monoxide, and hydroxylamine hydrochloride are used as starting materials, and the starting materials are subjected to copol...
|
|
WO/2022/088305A1 |
A purification method for an intermediate 4,4-dimethylisoxazol-3-one. The purification method comprises: washing a 4,4-dimethylisoxazol-3-one reaction solution by using pure water until the pH of the oil phase of the reaction solution is...
|
|
WO/2022/078305A1 |
A compound represented by general formula (I) or a stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, and a preparation method ther...
|
|
WO/2022/082197A1 |
Provided herein are polymorphs of 6-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4- yl)methoxy)piperidin-l-yl)-l-methyl-lH-indole-3-carboxylic acid, compositions thereof, methods of preparation thereof, and methods of use thereof.
|
|
WO/2022/076628A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis usin...
|
|
WO/2022/052969A1 |
The present invention elates to crystal forms I and II of cycloserine and a preparation method therefor. The crystal forms I and II have a uniform particle size distribution and a larger particle size, the crystal structure is similar to...
|
|
WO/2022/043374A1 |
The present invention relates to compounds of formula (II) wherein R1-R5, X and L are as described herein, and pharmaceutically acceptable salts thereof, compositions including the compounds and methods of using the compounds, particular...
|
|
WO/2022/040747A1 |
The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron. In particular embodiments, the compounds are compounds of formul...
|
|
WO/2022/043503A1 |
The present invention relates to c-di-GMP lowering chemical compounds having anti- biofilm properties. In particular, the present invention relates to anti-biofilm compounds or salts or tautomers thereof for use in treatment and/or preve...
|
|
WO/2022/026500A1 |
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...
|
|
WO/2022/017515A1 |
Provided in the present application are a diarylamine compound, a preparation method therefor and an application thereof. The compound has a structure represented by formula 1; R1 is selected from an alkyl group of C1-12, an alkoxy group...
|
|
WO/2022/009863A1 |
The present invention relates to a treatment agent for various diseases of the nervous system and mental illnesses which contains the compound represented in formula (1) or a pharmaceutically acceptable salt thereof as the active compone...
|
|
WO/2022/009044A1 |
The invention relates to a process for preparing immediate precursors for pyroxasulfone and fenoxasulfone preparation of the formula (I). The process comprises a bromination reaction of a benzylic position without light irradiation (step...
|
|
WO/2021/254445A1 |
The present invention relates to the technical field of pharmaceutical and chemical industry, and specifically, to a crystal form of a GABA inhibitor and a preparation method therefor. The GABA crystal form has the advantages of good pro...
|
|
WO/2021/255279A1 |
The invention relates to novel compounds of formulae (I') and (II') for the treatment, alleviation or prevention of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a compone...
|
|
WO/2021/245006A1 |
The invention relates to novel selective herbicidal active compound combinations which comprise substituted isoxazolincarboxamides or agrochemical acceptable salts thereof and furilazole and which can be used with particularly good resul...
|
|
WO/2021/245004A1 |
BCS201012 FC NR/ec 07.05.2021 - 39 - Selective herbicides based on substituted isoxazolin carboxamides and cloquintocet-mexyl A b s t r a c t The invention relates to novel selective herbicidal active compound combinations which comprise...
|
|
WO/2021/245008A1 |
The invention relates to novel selective herbicidal active compound combinations which comprise substituted isoxazolincarboxamides or agrochemical acceptable salts thereof and benoxacor and which can be used with particularly good result...
|
|
WO/2021/245003A1 |
The invention relates to novel selective herbicidal active compound combinations which comprise substituted isoxazolincarboxamides or agrochemical acceptable salts thereof and isoxadifen-ethyl and which can be used with particularly good...
|
|
WO/2021/245005A1 |
The invention relates to novel selective herbicidal active compound combinations which comprise substituted isoxazolincarboxamides or agrochemical acceptable salts thereof and cyprosulfamide and which can be used with particularly good r...
|
|
WO/2021/245009A1 |
The invention relates to novel selective herbicidal active compound combinations which comprise substituted isoxazolincarboxamides or agrochemical acceptable salts thereof and metcamifen and which can be used with particularly good resul...
|
|
WO/2021/245007A1 |
The invention relates to novel selective herbicidal active compound combinations which comprise substituted isoxazolincarboxamides or agrochemical acceptable salts thereof and mefenpyr-diethyl and which can be used with particularly good...
|
|
WO/2021/233851A1 |
The invention relates to a compound of formula (I) wherein R1-R2 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2021/228673A1 |
The invention relates to a process for preparing optically enriched isoxazoline compounds of formula (I) wherein the variables are as defined in the specification, and the shown enantiomer has at least 75% ee; by oxo-Michael addition of ...
|
|
WO/2021/230710A1 |
The present invention relates to a compound of chemical formula 1 or a salt thereof. The compound not only exhibits an excellent anticancer effect by inhibiting the activity of IDO and/or TDO, but also has a synergistic anticancer effect...
|
|
WO/2021/224040A1 |
The invention relates to compounds of formula (I), and their use as herbicides. In said formula, R1 to R6 represent groups such as hydrogen, halo-gen or organic groups such as alkyl, alkenyl, alkynyl, or alkoxy; W is a bicyclic heterocyc...
|
|
WO/2021/197880A1 |
The invention relates to a process for preparing optically enriched isoxazoline compounds of formula (I), formula (I), wherein the variables are as defined in the specification, and the shown enantiomer has at least 55% ee; by oxo-Michae...
|
|
WO/2021/183937A1 |
Tri-substituted isoxazole compounds and compound synthesis is disclosed. Tri-substituted isoxazole compounds having sodium gate channel Nav7 selectivity that are tunable for selectivity over Nav1.5. In particular, structure-activity rela...
|
|
WO/2021/176456A1 |
The invention relates to a process for preparing a key intermediate of Formula (I) in the synthesis of pyroxasulfone. The process comprises reacting an isoxazole of Formula (II) with a thionating reagent to create an ^-substituted thiois...
|
|
WO/2021/167008A1 |
This method for producing an aromatic astatine compound comprises reacting aromatic iodonium ylide with astatine to produce an aromatic astatine compound.
|
|
WO/2021/163348A2 |
The present technology is directed to compounds Formulas I, II, III, and IV as well as compositions that include one or more of the compounds and methods of making the compounds. In particular, the present compounds may be used as a repl...
|
|
WO/2021/143762A1 |
Disclosed are a compound of formula (I), wherein the variables are defined in the specification, a pharmaceutical composition containing the same, and a method and a use of the compound or composition in the treatment of a PCSK9-mediated...
|
|
WO/2021/132311A1 |
The present invention relates: to a compound represented by formula (1), the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In...
|
|
WO/2021/127188A1 |
The present invention provides compounds of formula (I): which are useful for long-lasting treatment and control of pests, for example fleas and ticks, in companion animals and livestock, and pharmaceutical compositions and methods of us...
|
|
WO/2021/122356A1 |
The invention relates to an improved process for the synthesis of Fluralaner in an efficient and economical way.
|
|
WO/2021/113284A1 |
A method for preparing a compound of Formula (1) and compounds therefrom, comprising treating a compound of Formula (2) to provide a compound of Formula (5) and treating the compound of Formula (5) with a hydroxylamine salt wherein R1, R...
|
|
WO/2021/113806A1 |
The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating dis...
|
|
WO/2021/104427A1 |
A crystalline form A of a nitrogen-containing tricyclic compound shown in formula (I), a pharmaceutical composition comprising the crystalline form A, and the use of the crystalline form A or the pharmaceutical composition in the prepara...
|
|
WO/2021/104421A1 |
The present invention relates to an amorphous form of a nitrogen-containing tricyclic compound and a use thereof, a pharmaceutical composition containing the compound in the amorphous form, and the use of the compound in the amorphous fo...
|
|
WO/2021/108198A1 |
Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
|
|
WO/2021/102569A1 |
This disclosure relates generally to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives for the treatment of conditions associated with cannabinoid receptor.
|
|
WO/2021/102568A1 |
This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is - CH2CH=C(CH3)2, R2...
|
|
WO/2021/105261A1 |
Disclosed are TRPM8 modulators as defined by formula (I) for achieving a cooling effect on skin and mucousa.
|
|
WO/2021/102896A1 |
Disclosed are TRPM8 modulators as defined by formula (I) for achieving a cooling effect on skin and mucousa.
|
|
WO/2021/098703A1 |
Disclosed are a class of compounds having a highly selective inhibition of ROS1, and the use thereof in the preparation of drugs for treating diseases related to abnormal ROS1 kinase expression. Specifically disclosed are compounds repre...
|
|
WO/2021/102115A1 |
The present disclosure provides processes for preparing an alpha-hydroxy ester by addition of a vinyl Grignard reagent to an oxalate ester and thiolation of the resulting double bond. Also provided are alpha-hydroxy esters and synthetic ...
|
|
WO/2021/092474A1 |
Provided herein are methods and compositions for treating liver disorders, including without limitation non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient.
|
